Business
XTL Update on Recent Developments
RAMAT GAN, ISRAEL, Jan. 29, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the “Company” or “XTL”), announced that it is working diligently to close the acquisition of 85% of the shares of NeuroNOS Ltd. from Beyond Air Inc, following the execution of the Binding Letter of Intent on January 13 , 2026 (as disclosed in the Company’s Report of Foreign Private Issuer on Form 6-K filed on January 13, 2026), and has already scheduled a shareholders meeting for Februa
About this update from Xtl Biopharmaceuticals Ltd.
[{"type":"image","alt":"XTL Biopharmaceuticals Ltd.","displaySize":"","headline":null,"caption":"XTL Biopharmaceuticals Ltd.","className":"","disableSlideshowImg":false,"size":{"original":{"width":191,"height":58,"url":"https://media.zenfs.com/en/globenewswire.com/ec9b45c6e485e8fa9ea9e6572969aa56"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/tncNbvxX6xpdFdrOo.ctLw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTEwOTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/ec9b45c6e485e8fa9ea9e6572969aa56","width":191,"height":58}},"lazy":false},{"type":"text","content":"RAMAT GAN, ISRAEL, Jan. 29, 2026 (GLOBE NEWSWIRE) -- XTL Biopharmaceuticals Ltd. (Nasdaq:XTLB) (TASE:XTLB.TA) (the “Company” or “XTL”), announced that it is working diligently to close the acquisition of 85% of the shares of NeuroNOS Ltd. from Beyond Air Inc, following the execution of the Binding Letter of Intent on January 13 , 2026 (as disclosed in the Company’s Report of Foreign Private Issuer on Form 6-K filed on January 13, 2026), and has already scheduled a shareholders meeting for February 17, 2026 to approve a private placement of up to US$2 million.","length":570,"tagName":"p"},{"type":"text","content":"Management of the Company believes that the completion of the proposed transaction to acquire 85% of the shares of NeuroNOS Ltd., as well as the private placement, will remedy its deficiency under Nasdaq Listing Rule 5550(b)(1) to maintain a minimum of $2,500,000 in stockholders’ equity. The Company is currently working to submit to Nasdaq a plan to regain compliance with this Nasdaq Listing Rule. However, there can be no assurance at this point that the proposed acquisition will close in a timely manner or at all or that shareholders will approve the private placement in a timely manner or at all, nor can there be any assurance that Nasdaq will approve the Company’s plan, that the Company will regain compliance with the stockholders’ equity rule, or that the Company will maintain compliance with any of Nasdaq’s other listing rules.","length":844,"tagName":"p"},{"type":"text","content":"About XTL Biopharmaceuticals Ltd.","length":38,"tagName":"p"},{"type":"text","content":"XTL is an IP Portfolio company that holds 100% of The Social Proxy Ltd. and IP portfolio including hCDR1 for Lupus (SLE) and Sjögren's Syndrome (SS) that the company sublicensed. The company actively pur...